Age affects drug survival rates of interleukin (<scp>IL</scp>)‐17 and <scp>IL</scp>‐23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi‐country, cohort study-Reference-Cited by-同舟云学术

Age affects drug survival rates of interleukin (IL)‐17 and IL‐23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi‐country, cohort study

Published:2024-06-11 Issue: Volume: Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Chiricozzi Andrea¹²^ORCID,Coscarella Giulia¹²,Puig Luis³^ORCID,Vender Ron⁴^ORCID,Yeung Jensen⁵,Carrascosa José‐Manuel⁶^ORCID,Piaserico Stefano⁷,Gisondi Paolo⁸^ORCID,Lynde Charles⁹,Ferreira Paulo¹⁰,Bastos Pedro Mendes¹⁰^ORCID,Dauden Esteban¹¹^ORCID,Leite Luiz¹²,Valerio Joana¹²,del Alcázar‐Viladomiu Elena⁶^ORCID,Vilarrasa Eva³,Llamas‐Velasco Mar¹¹^ORCID,Alessandri‐Bonetti Mario¹³,Messina Francesco⁷^ORCID,Bruni Manfredo⁸,Di Brizzi Eugenia Veronica¹⁴^ORCID,Ricceri Federica¹⁵^ORCID,Nidegger Alessia¹⁶,Hugo Jan¹⁷^ORCID,Mufti Asfandyar⁵,Daponte Athina‐Ioanna¹⁸,Teixeira Laetitia¹⁹,Balato Anna¹⁴,Romanelli Marco²⁰,Prignano Francesca¹⁵^ORCID,Gkalpakiotis Spyridon¹⁷^ORCID,Conrad Curdin¹⁶^ORCID,Lazaridou Elizabeth¹⁸,Rompoti Natalia²¹^ORCID,Stratigos Alexander J.²¹,Nogueira Miguel²²^ORCID,Peris Ketty¹²^ORCID,Torres Tiago²²²³²⁴^ORCID

Affiliation:

1. Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale Università Cattolica Del Sacro Cuore Rome Italy

2. Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy

3. Department of Dermatology Hospital de la Santa Creu i Sant Pau Barcelona Spain

4. McMaster University Hamilton Ontario Canada

5. Division of Dermatology, Department of Medicine, Probity Medical Research University of Toronto Waterloo Ontario Canada

6. Department of Dermatology, Germans Trias i Pujol University Hospital (HUGTP) Autonomous University of Barcelona (UAB) Badalona Spain

7. Dermatology Unit, Department of Medicine University of Padua Padua Italy

8. Section of Dermatology and Venereology, Department of Medicine University of Verona Verona Italy

9. Department of Medicine, The Lynde Institute for Dermatology University of Toronto Toronto Ontario Canada

10. Dermatology Center Hospital CUF Descobertas Lisbon Portugal

11. Dermatology Department Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria La Princesa (IIS‐IP) Madrid Spain

12. Clínica Médica Belém Lisbon Portugal

13. Department of Reconstructive and Aesthetic Plastic Surgery University of Milan Milan Italy

14. Unit of Dermatology – University of Campania Luigi Vanvitelli Naples Italy

15. Section of Dermatology, Department of Dermatological Science University of Florence Florence Italy

16. Department of Dermatology Lausanne University Hospital CHUV and University of Lausanne Lausanne Switzerland

17. Department of Dermatovenereology, Third Faculty of Medicine Charles University and Kralovske Vinohrady University Hospital Prague Czech Republic

18. Second Department of Dermatology‐Venereology Aristotle University School of Medicine Thessaloniki Greece

19. Center for Health Technology and Services Research (CINTESIS) Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS.UP) Porto Portugal

20. Department of Dermatology University of Pisa Pisa Italy

21. University Hospital of Venereal and Skin Diseases “A.Sygros” Athens Greece

22. Department of Dermatology CAC ICBAS‐CHP – Centro Académico Clínico ICBAS – CHP Porto Portugal

23. UMIB – Unit for Multidisciplinary Research in Biomedicine Instituto de Ciências Biomédicas Abel Salazar, University of Porto Porto Portugal

24. ITR – Laboratory for Integrative and Translational Research in Population Health Porto Portugal

Abstract

AbstractBackgroundScarce data related to the drug survival of biologic agents in psoriasis patients aged ≥65 years is available.ObjectivesTo evaluate the drug survival of interleukin (IL)‐23 or the IL‐17 inhibitors approved for the treatment of moderate‐to‐severe psoriasis in elderly patients (aged ≥65 years), compared with younger adult patients (aged <65 years), and to identify clinical predictors that can influence the drug survival.MethodsThis retrospective multicentric cohort study included adult patients with moderate‐to‐severe psoriasis, dissecting two‐patient subcohorts based on age: elderly versus younger adults. Kaplan–Meier estimator and proportional hazard Cox regression models were used for drug survival analysis.ResultsWe included 4178 patients and 4866 treatment courses; 934 were elderly (1072 treatment courses), and 3244 were younger patients (3794 treatment courses). Drug survival, considering all causes of interruption, was higher in patients aged <65 years than in elderly patients overall (log‐rank p < 0.006). This difference was significant for treatment courses involving IL‐23 inhibitors (p < 0.001) but not for those with IL‐17 inhibitors (p = 0.2). According to both uni‐ and multi‐variable models, elder age was associated with an increased risk of treatment discontinuation (univariable analysis: HR: 1.229, 95% CI 1.062–1.422; p < 0.006; multivariable analysis: HR: 1.199, 95% CI 1.010–1.422; p = 0.0377). Anti‐IL‐23 agents were associated with a reduced likelihood of treatment discontinuation after adjusting for other variables (HR: 0.520, 95% CI 0.368–0.735; p < 0.001). Being previously treated with IL‐17 inhibitors increased the probability of discontinuation.ConclusionElderly patients with psoriasis have an increased risk of biologic treatment discontinuation compared with younger adult patients, particularly, if being treated with IL‐23 inhibitors. However, in stratified analyses conducted in elderly patients, IL‐23 inhibitors showed higher drug survival rates than IL‐17 inhibitors.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.20143

Reference31 articles.

1. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis

2. Efficacy, safety, and drug survival of IL‐23, IL‐17, and TNF‐alpha inhibitors for psori‐ asis treatment: a retrospective study;Dapavo P;J Dermatol Treat,2021

3. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review

4. Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-Analysis

5. Real‐world, long‐term treatment patterns of commonly used biologics in Canadian patients with moderate‐to‐severe chronic plaque psoriasis